Effects of Omalizumab on Rhinovirus Infections, Illnesses, and exacerbations of asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 196, Issue 8, 2017, Pages 985-992

  Esquivel, Ann ^a   Busse, William W ^a   Calatroni, Agustin ^b   Togias, Alkis G ^c   Grindle, Kristine G ^a   Bochkov, Yury A ^a   Gruchalla, Rebecca S ^d   Kattan, Meyer ^e   Kercsmar, Carolyn M ^f   Hershey, G Khurana ^f   Kim, Haejin ^g   Lebeau, Petra ^b   Liu, Andrew H ^h,i   Szefler, Stanley J ⁱ   Teach, Stephen J ^j   West, Joseph B ^k   Wildfire, Jeremy ^b   Pongracic, Jaqueline A ^l   Gern, James E ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b RHO INC   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e Department of Medicine   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g HENRY FORD HEALTH SYSTEM   (United States)

^h DEPARTMENT OF MEDICINE   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^k BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l CHILDREN'S MEMORIAL HOSPITAL   (United States)

more..

Author keywords

Asthma; IgE; Omalizumab; Rhinovirus

Indexed keywords

IMMUNOGLOBULIN E; OMALIZUMAB; PLACEBO; ANTIASTHMATIC AGENT;

ADOLESCENT; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE DURATION; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN RHINOVIRUS A; HUMAN RHINOVIRUS B; INFECTION; MAJOR CLINICAL STUDY; MALE; NOSE MUCUS; NOSE SECRETION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RHINOVIRUS INFECTION; SEVERE PERSISTENT ASTHMA; UNITED STATES; VIRUS DETECTION; VIRUS SHEDDING; ASTHMA; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; MULTICENTER STUDY; RHINOVIRUS; VIRUS DISEASES;

ADOLESCENT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; FEMALE; HUMANS; MALE; OMALIZUMAB; RHINOVIRUS; UNITED STATES; VIRUS DISEASES;

EID: 85031699574     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201701-0120OC     Document Type: Article

References (41)

1. Olenec JP, Kim WK, Lee WM, Vang F, Pappas TE, Salazar LE, Evans MD, Bork J, Roberg K, Lemanske RF Jr, et al. Weekly monitoring of children with asthma for infections and illness during common cold seasons. J Allergy Clin Immunol 2010;125:1001-1006.e1.
2. Linder JE, Kraft DC, Mohamed Y, Lu Z, Heil L, Tollefson S, Saville BR, Wright PF, Williams JV, Miller EK. Human rhinovirus C: age, season, and lower respiratory illness over the past 3 decades. J Allergy Clin Immunol 2013;131:69-77.e6.
3. Bizzintino J, Lee WM, Laing IA, Vang F, Pappas T, Zhang G, Martin AC, Khoo SK, Cox DW, Geelhoed GC, et al. Association between human rhinovirus C and severity of acute asthma in children. Eur Respir J 2011;37:1037-1042.
4. Cox DW, Bizzintino J, Ferrari G, Khoo SK, Zhang G, Whelan S, Lee WM, Bochkov YA, Geelhoed GC, Goldblatt J, et al. Human rhinovirus species C infection in young children with acute wheeze is associated with increased acute respiratory hospital admissions. Am J Respir Crit Care Med 2013;188:1358-1364.
5. Iwane MK, Prill MM, Lu X, Miller EK, Edwards KM, Hall CB, Griffin MR, Staat MA, Anderson LJ, Williams JV, et al. Human rhinovirus species associated with hospitalizations for acute respiratory illness in young US children. J Infect Dis 2011;204:1702-1710.
6. Mak RK, Tse LY, Lam WY, Wong GW, Chan PK, Leung TF. Clinical spectrum of human rhinovirus infections in hospitalized Hong Kong children. Pediatr Infect Dis J 2011;30:749-753.
7. Drysdale SB, Alcazar M, Wilson T, Smith M, Zuckerman M, Lauinger IL, Tong CY, Broughton S, Rafferty GF, Johnston SL, et al. Respiratory outcome of prematurely born infants following human rhinovirus A and C infections. Eur J Pediatr 2014;173:913-919.
8. Jackson DJ, Evans MD, Gangnon RE, Tisler CJ, Pappas TE, Lee WM, Gern JE, Lemanske RF Jr. Evidence for a causal relationship between allergic sensitization and rhinovirus wheezing in early life. Am J Respir Crit Care Med 2012;185:281-285.
9. Kantor DB, Stenquist N, McDonald MC, Schultz BJ, Hauptman M, Smallwood CD, Nelson KA, Perzanowski MS, Matsui EC, Phipatanakul W, et al. Rhinovirus and serum IgE are associated with acute asthma exacerbation severity in children. J Allergy Clin Immunol 2016;138:1467-1471.e9.
10. Platts-Mills TA, Rakes G, Heymann PW. The relevance of allergen exposure to the development of asthma in childhood. J Allergy Clin Immunol 2000;105:S503-S508.
11. Duff AL, Pomeranz ES, Gelber LE, Price GW, Farris H, Hayden FG, Platts-Mills TA, Heymann PW. Risk factors for acute wheezing in infants and children: viruses, passive smoke, and IgE antibodies to inhalant allergens. Pediatrics 1993;92:535-540.
12. Heymann PW, Carper HT, Murphy DD, Platts-Mills TA, Patrie J, McLaughlin AP, Erwin EA, Shaker MS, Hellems M, Peerzada J, et al. Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing. J Allergy Clin Immunol 2004;114:239-247.
13. Rakes GP, Arruda E, Ingram JM, Hoover GE, Zambrano JC, Hayden FG, Platts-Mills TA, Heymann PW. Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care: IgE and eosinophil analyses. Am J Respir Crit Care Med 1999;159:785-790.
14. Teach SJ, Gergen PJ, Szefler SJ, Mitchell HE, Calatroni A, Wildfire J, Bloomberg GR, Kercsmar CM, Liu AH, Makhija MM, et al. Seasonal risk factors for asthma exacerbations among inner-city children. J Allergy Clin Immunol 2015;135:1465-1473.e5.
15. Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ Jr, Calatroni A, Wildfire JJ, Gergen PJ, Cohen RT, Pongracic JA, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol 2015; 136:1476-1485.
16. Kantor DB, McDonald MC, Stenquist N, Schultz BJ, Smallwood CD, Nelson KA, Phipatanakul W, Hirschhorn JN. Omalizumab is associated with reduced acute severity of rhinovirus-triggered asthma exacerbation. Am J Respir Crit Care Med 2016;194:1552-1555.
17. Gill MA, Bajwa G, George TA, Dong CC, Dougherty II, Jiang N, Gan VN, Gruchalla RS. Counterregulation between the FceRI pathway and antiviral responses in human plasmacytoid dendritic cells. J Immunol 2010;184:5999-6006.
18. Durrani SR, Montville DJ, Pratt AS, Sahu S, DeVries MK, Rajamanickam V, Gangnon RE, Gill MA, Gern JE, Lemanske RF Jr, et al. Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children. J Allergy Clin Immunol 2012;130:489-495.
19. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, Gruchalla RS, Kattan M, Teach SJ, Pongracic JA, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011;364:1005-1015.
20. Jackson GG, Dowling HF, Spiesman IG, Boand AV. Transmission of the common cold to volunteers under controlled conditions. I. The common cold as a clinical entity. AMA Arch Intern Med 1958;101: 267-278.
21. Bochkov YA, Grindle K, Vang F, Evans MD, Gern JE. Improved molecular typing assay for rhinovirus species A, B, and C. J Clin Microbiol 2014;52:2461-2471.
22. Soto-Quiros M, Avila L, Platts-Mills TA, Hunt JF, Erdman DD, Carper H, Murphy DD, Odio S, James HR, Patrie JT, et al. High titers of IgE antibody to dust mite allergen and risk for wheezing among asthmatic children infected with rhinovirus. J Allergy Clin Immunol 2012;129:1499-1505.e5.
23. Gielen V, Sykes A, Zhu J, Chan B, Macintyre J, Regamey N, Kieninger E, Gupta A, Shoemark A, Bossley C, et al. Increased nuclear suppressor of cytokine signaling 1 in asthmatic bronchial epithelium suppresses rhinovirus induction of innate interferons. J Allergy Clin Immunol 2015;136:177-188.e11.
24. Lynch JP, Werder RB, Simpson J, Loh Z, Zhang V, Haque A, Spann K, Sly PD, Mazzone SB, Upham JW, et al. Aeroallergen-induced IL-33 predisposes to respiratory virus-induced asthma by dampening antiviral immunity. J Allergy Clin Immunol 2016;138:1326-1337.
25. Chen G, Korfhagen TR, Karp CL, Impey S, Xu Y, Randell SH, Kitzmiller J, Maeda Y, Haitchi HM, Sridharan A, et al. Foxa3 induces goblet cell metaplasia and inhibits innate antiviral immunity. Am J Respir Crit Care Med 2014;189:301-313.
26. Sly PD, Boner AL, Björksten B, Bush A, Custovic A, Eigenmann PA, Gern JE, Gerritsen J, Hamelmann E, Helms PJ, et al. Early identification of atopy in the prediction of persistent asthma in children. Lancet 2008;372:1100-1106.
27. Cheung DH, Tsang TK, Fang VJ, Xu J, Chan KH, Ip DK, Peiris JS, Leung GM, Cowling BJ. Association of oseltamivir treatment with virus shedding, illness, and household transmission of influenza viruses. J Infect Dis 2015;212:391-396.
28. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014; (4):CD008965.
29. Hayden FG, Herrington DT, Coats TL, Kim K, Cooper EC, Villano SA, Liu S, Hudson S, Pevear DC, Collett M, et al.; Pleconaril Respiratory Infection Study Group. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis 2003;36:1523-1532.
30. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014;348:g2545.
31. Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J, Erpenbeck VJ, Holgate S. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract 2014;2:525-536.e1.
32. Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 2009;64:1728-1736.
33. van Rensen EL, Evertse CE, van Schadewijk WA, van Wijngaarden S, Ayre G, Mauad T, Hiemstra PS, Sterk PJ, Rabe KF. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy 2009;64:72-80.
34. Ingram JM, Rakes GP, Hoover GE, Platts-Mills TA, Heymann PW. Eosinophil cationic protein in serum and nasal washes from wheezing infants and children. J Pediatr 1995;127:558-564.
35. Nakagome K, Bochkov YA, Ashraf S, Brockman-Schneider RA, Evans MD, Pasic TR, Gern JE. Effects of rhinovirus species on viral replication and cytokine production. J Allergy Clin Immunol 2014; 134:332-341.
36. Lee WM, Lemanske RF Jr, Evans MD, Vang F, Pappas T, Gangnon R, Jackson DJ, Gern JE. Human rhinovirus species and season of infection determine illness severity. Am J Respir Crit Care Med 2012; 186:886-891.
37. Jackson GG, Dowling HF, Anderson TO, Riff L, Saporta J, Turck M. Susceptibility and immunity to common upper respiratory viral infections-the common cold. Ann Intern Med 1960;53:719-738.
38. Gern JE. Virus/allergen interaction in asthma exacerbation. Ann Am Thorac Soc 2015;12(Suppl 2):S137-S143.
39. Kloepfer KM, Lee WM, Pappas TE, Kang TJ, Vrtis RF, Evans MD, Gangnon RE, Bochkov YA, Jackson DJ, Lemanske RF Jr, et al. Detection of pathogenic bacteria during rhinovirus infection is associated with increased respiratory symptoms and asthma exacerbations. J Allergy Clin Immunol 2014;133:1301-1307.e3.
40. Bisgaard H, Hermansen MN, Bønnelykke K, Stokholm J, Baty F, Skytt NL, Aniscenko J, Kebadze T, Johnston SL. Association of bacteria and viruses with wheezy episodes in young children: prospective birth cohort study. BMJ 2010;341:c4978.
41. National Asthma Education and Prevention Program. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007;120: S94-S138.